USANA Health Sciences, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2016. The filing is an annual report, not a 2015 Q4 filing as indicated in the request. Fiscal 2016 and 2015 each comprised 52 weeks; 2014 comprised 53 weeks.
Business context and results
USANA develops and manufactures nutrition and personal-care products, selling through independent direct-selling Associates and Preferred Customers in 20 markets. It reported 471,000 active Associates and 93,000 active Preferred Customers at year-end. About 87% of 2016 sales came from outside the United States.
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Net sales | $1,006.1 million | $918.5 million |
| Gross profit / margin | $825.9 million / 82.1% | $758.8 million / 82.6% |
| Operating earnings / margin | $138.6 million / 13.8% | $141.7 million / 15.4% |
| Net earnings / net margin | $100.0 million / 9.9% | $94.7 million / 10.3% |
| Diluted EPS | $3.99 | $3.59 |
| Operating cash flow | $137.0 million | $111.5 million |
Sales rose 9.5% year over year; management estimated adverse currency effects reduced sales by $41.6 million, while constant-currency sales grew 14.1%. Asia Pacific sales increased 13.5% to $754.4 million and accounted for 75% of revenue. Americas and Europe sales were nearly flat at $251.6 million. China sales were $437.4 million; U.S. sales declined 6.9% to $130.4 million.
Associate incentives were 45.0% of sales versus 44.4% in 2015; SG&A was 23.3% versus 22.8%. The 50-basis-point gross-margin decline reflected currency and inefficiencies during the move to the new China manufacturing facility, partly offset by market mix and price adjustments. Net earnings increased 5.7%, but operating earnings declined as expenses grew faster than sales. The effective tax rate fell to 27.8% from 33.6%, largely due to early adoption of share-based compensation accounting; management attributed $0.30 of 2016 diluted EPS to that adoption.
Cash, liquidity, debt, and capital allocation
Cash and equivalents were $175.8 million at year-end, up from $143.2 million; working capital was $139.4 million, up from $112.9 million. Operating cash flow was $137.0 million, capital expenditures were $32.7 million, and cash used in share repurchases was $64.6 million. The company repurchased 1.1 million shares and had $35.4 million remaining under its authorized repurchase plan.
There was no outstanding debt at year-end. USANA had a $75 million revolving credit facility maturing in April 2021, subject to financial covenants; existing guarantees reduced availability by $5.2 million. Management expects cash, operating cash flow, and available credit to cover ordinary operating and capital needs for the foreseeable future. The filing does not provide a quantified 2017 earnings or revenue forecast. Of year-end cash, $155.7 million was held internationally; repatriating $19.6 million of indefinitely reinvested earnings was estimated to incur $3.1 million in tax.
Outlook, risks, contingencies, and unusual items
- Management plans to focus on China, continue market-specific promotions and customer-growth initiatives, expand Preferred Customer programs, and invest further in product innovation, IT, infrastructure, and R&D. It described China and Indonesia as growth opportunities, while noting that U.S. customer and sales trends have been weak. The MySmart Foods launch and reception did not meet expectations; the company was evaluating enhancements to the line.
- Foreign exchange is a major exposure: 87% of sales were international, and currency movements reduced reported 2016 sales. China also entails regulatory and licensing uncertainty; eight of BabyCare’s 12 direct-selling licenses granted in 2016 remained subject to conditions and reporting requirements.
- The company disclosed a voluntary internal investigation into BabyCare’s China operations, including possible FCPA compliance issues and expense-reimbursement practices. It notified the SEC and DOJ. The investigation was at an early stage, and its scope, duration, and outcome were unknown; potential costs, penalties, or other government action could not be quantified.
- USANA identified a material weakness in internal control over financial reporting involving China management override, inadequate compliance training, and deficient controls over cash disbursements and supporting documentation. Management reported no resulting material financial-statement misstatement, but concluded controls were ineffective; KPMG issued an adverse opinion on ICFR while issuing an unqualified opinion on the financial statements. Remediation was expected during 2017, subject to testing.
- A putative shareholder class action filed in February 2017 alleges securities-law violations related to the China matters; USANA said it would vigorously defend the case. The company had not accrued for contingencies at year-end because it considered none probable and estimable, while acknowledging some reasonably possible matters could not then be estimated.
- Other notable exposures include direct-selling and product regulation, dependence on independent Associates, foreign-exchange movements, supplier and manufacturing continuity, competition, and cybersecurity. The company reported no material product-return burden: returns were approximately 0.7% of sales in 2016.
Most important facts for investors to verify
- Progress, findings, costs, and any regulatory or litigation consequences of the BabyCare investigation and related shareholder action.
- Whether the China internal-control material weakness is remediated and controls operate effectively; review the auditor’s adverse ICFR opinion and planned remediation.
- China license conditions, additional license approvals, and the sustainability of China growth amid regulatory uncertainty.
- Whether sales growth, customer additions, and product launches translate into operating profit and margin recovery, particularly given higher incentive and SG&A ratios.
- Ongoing currency impact, international cash accessibility, capital spending, repurchases, and compliance with the revolving-credit covenants.